Bob-
There are two very different uses of ADT.
One doesn't worry about
castrate-resistance setting in when ADT is used adjuvantly. You're not on it long enough for that to happen -- it usually takes many years.
The other use, which does
not apply in your case, is when all curative therapies are exhausted, and ADT is used, continuously or intermittently, to keep the cancer from progressing. So far, I have not seen any evidence that starting it earlier in that setting results in shorter survival. The
most recent study, a retrospective data analysis, showed that survival was not reduced by starting later, but it did not show significantly shorter survival by starting earlier. This is controversial, and it remains for a randomized clinical trial to provide proof.
There is no evidence that I'm aware of to support your conjecture that Lupron maintenance therapy might be less effective after it has been used adjuvantly with SRT.
- Allen